Review the side-effects of Lutetium Lu 177 Dotatate as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...
Discover comprehensive details about Lutetium Lu 177 Dotatate, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...
Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver ...
The FDA has given tentative approval to the abbreviated new drug application (ANDA) for PNT2003, a radioequivalent version of lutetium Lu 177 dotatate (Lutathera) indicated for treatment of ...
BEDFORD, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians ...
A recent study reported in the May issue of the Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in ...
Lu-177 dotatate is a molecular therapy. It is a type of peptide receptor radionuclide therapy (PRRT) used mainly for neuroendocrine tumors (NETs). PRRT combines a compound called a peptide with a ...
Toronto, Ontario—A novel imaging approach— 68 Ga-DOTATATE PET/CT—can more accurately differentiate residual/recurrent tumors from post-surgery scar tissue in patients with head and neck paragangliomas ...
NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive ...
Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma. NAPOLI-3: An open-label, randomized, phase III study of ...
The newly developed [55Co]55Co-DOTATATE imaging agent has emerged as a more accurate and sensitive radiopharmaceutical to aid in the diagnosis of neuroendocrine tumor metastases. According to research ...
The newly developed [55Co]55Co-DOTATATE imaging agent has emerged as a more accurate and sensitive radiopharmaceutical to aid in the diagnosis of neuroendocrine tumor metastases. According to research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results